By Sriparna Roy and Bhanvi Satija (Reuters) -Shares of global vaccine makers were muted on Tuesday as investors and analysts ...

By Sriparna Roy and Bhanvi Satija (Reuters) -Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

Vaccine maker stocks are steady despite RFK Jr.'s decision to fire all members of the CDC expert panel on immunizations. Read ...